www.neurologiepropraxi.cz / Neurol. Praxi. 2024;25(2):135-145 / NEUROLOGIE PRO PRAXI 145 Z POMEZÍ NEUROLOGIE Serotoninový syndrom a léčba bolesti LITERATURA 1. Ailawadhi S, Sung K‑W, Carlson LA, Baer MR: Serotonin syndrome cyused by interaction between citalopram and fentanyl. J Clin Pharmacoy Therap. 2007;32:199-202. 2. Ansari H, Kouti L. Drug interaction and serotonin toxicity with opioid use: another reason to avoid opioids in headache and migraine treatment. Curr Pain Headache Rep. 2016;20:60. doi: 10.1007/c11916-016-1579-3. 3. Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 2018; https://doi.org/10.1007/s00204-018-2244-6. 4. Baldo BA, Rose MA. The anaestetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Brit J Anaesth. 2020;124(1):44-62. 5. Baldo BA. Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity serotonin toxicity. ArchToxicol. 2021; https://doi.org/10.1007/s00204-021-03068-2. 6. Barann M, Stamer UM, Lyutenska M, et al. Effects of opioids on human serotonin transporters. Naunyn‑Schmiedaberg’s Arch Pharmacol. 2015;388:43-49. 7. Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20:S2-S12. 8. Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Phys. 2015;18:395400. 9. Boyer EW, Shannon M. The Serotonin syndrome. N Engl J Med. 2005;352:1112-20. 10. Dizdarevic A, Bremer N. Cervical spinal cord stimulation with concomitant serotonin norepinephrine reuptake inhibitor therapy leading to the serotonin syndrome. Pain Med. 2017;18:1199-1202. 11. Duma SR, Fung VSC. Drug‑induced movement disorders. Aust Prescr. 2019;42:56-61. 12. Dunkley EJC, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: sinple and accurate diagnostic decision rules for serotonin toxicity. Q J Med. 2003;96:635-42. 13. FDA Drug safety communications. FDA warns about several safety issues with opioid pain medicines; requires label changes. March 22, 2016. https ://www.fda.gov/downl oads/Drugs /DrugSafety /UCM49 1302.pdf. 14. Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Phys. 2018;64(10):720-727. 15. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The serotonin syndrome: from molecular mechanisms to clinical practice. Int J Molecul Sci. 2019;20:2288. doi:10.3390/ijms20092288 16. Fujáková M, Kopeček M. Antidepresiva – od teorie ke klinické praxi. Klin Farmakol Farm. 2012;26(1):29-37. 17. Gayle JA, Abadie JV, Kaye AM, Kaye AD. Serotonin syndrome. In: A.D. Kaye et al. (eds.), Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Springer Science+Business Media New York. 2015:797-807. doi: 10.1007/9781-4614-8948-1_49. 18. Gressler LE, Hammond DA, Painter JT. Serotonin syndrome in tapentadol literature: systematic review of original research. J Pain Palliat Care Pharmacotherapy. 2017;31(3-4):228-236. 19. Höschl C. Neurotrofní účinky antidepresiv. Available from: http://www.hoschl.cz/files/445_cz_Neurotrofni%20AD.pdf. 20. Jones D, Story DA. Serotonin syndrome and the anaesthetist. Anaesth Intensive Care. 2005;33:181-87. 21. Kanova K, Kohout P. Serotonin – its synthesis and roles in the healthy and the critically ill. Int J Med Sci. 2021;22:4873. 22. Koury KM, Tsui B, Gulur P. Incidence of serotonine syndrome in patients treated with fentanyl on serotoninergic agents. Pain Phys. 2015;18:E27-E30. 23. Malcolm B, Thomas K. Serotonin toxicity of serotoninergic psychedelics. Psychopharmacology. 2022;239(6):1881-1891. 24. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine. 2000;79(4):201-209. 25. Mastroianni A, Ravaglia G. Serotonin syndrome due to co‑administration of linezolid and methadone. Infez Med. 2017;25(3):263-66. 26. Mohr P. Serotoninový syndrom – diagnostika, terapie, prevence. Psych Praxi. 2001;3:117-20. 27. Nelson EM, Philbrick AM: Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors. Ann Pharmacother. 2012;46:1712-16. 28. Prakash S, Adroja B, Parekh H. Serotonin syndrome in patients with headache disorders. BMJ Case Rep. 2017. doi:10.1136/ bcr-2017-221383. 29. Prakash S, Rathore C, Rana K, Patel H. Antiepileptic drugs and serotonin syndrome – a systematic review of case series and case reports. Seizure Eur J Epil. 2021;91:117-31. 30. Praško J, Prašková H. Farmakoterapie deprese. Psychiat. Praxi. 2006;5:214-224. 31. Prokeš M, Suchopár J. Serotoninový syndrom: co bychom o něm měli vědět. Med Praxi. 2014;11(5):226-230. 32. Rastogi R, Swarm RA, Patel TA. Case scenarion: opioid assiciation with serotonin syndrome. Implications to the practitioners. Anesthesiology. 2011;115(6):1291-98. 33. Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid‑induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Brit J Prarmacol. 2018;175:532-543. 34. Roulet L, Rollason V, Desmeules J, Piguet V. Tapentadol versus tramadol: a narrative and comparative review of ther pharmacological, efficacy and safety profiles in adult patients. Drugs. 2021;81:1257-72. 35. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: patophysiology, clinical features, management, and potential ruture directions. Int J Tryptoph Res. 2019;12(1):1-14. 36. Shelton RC. Serotonin and norepinephrine reuptake inhibitors. Handbook of Experimental Pharmacology, Springer Nature Switzerland AG 2018. Available from: https://doi. org/10.1007/164_2018_164. 37. Spadaro A, Scott KR, Koyfman A, Long B. High risk and low prevalence disease: serotonin syndrome. Am J Emerg Med. 2022;61:90-97. 38. SPC: Peritol 4 mg https://www.sukl.cz/modules/medication/detail.php?code=0219901 & tab=texts. 39. Tašková I. Úzkostné poruchy a jejich léčba. Prakt Lékáren. 2021;17(4):207-212. 40. Tormoehlen LM, Rusyniak DE. Neuroleptic malignant syndrome and serotonin syndrome. In: Romanovsky AA: Handbook of clinical neurology, 3rd Series, Elsevier 2018:663-675. 41. UpToDate 2023. Available from: https://www.uptodate.com/ contents/image?imageKey=EM%2F71268. 42. Vaněk J. Serotoninový syndrom – častý problém, či vzácná komplikace? Prakt. Lékáren. 2022;18(2):75-78. 43. Vojtíšek P, Nalos D. Serotoninergní syndrom – kazuistika. Anest Intenziv Mad. 2011;22(3):159-162. 44. Werneke U, Truedson‑Martiniussen P, Wikström H, Ott M. Serotonin syndrome: a clinical review of current controversies. J Integr Neurosci. 2020;19(4):719-727. 45. Zakharov S. Toxikologie nových rekreačních drog. Available from: https://postudium.cz/mod/book/view. php?id=1243 & chapterid=522. ČESKÝ A SLOVENSKÝ NEUROLOGICKÝ SJEZD 37. 27.–29. 11. 2024 | CLARION CONGRESS HOTEL OSTRAVA Těšíme se na setkání s Vámi v listopadu 2024 v Ostravě! • www.csns2024.cz
RkJQdWJsaXNoZXIy NDA4Mjc=